The estimated Net Worth of Steven J Keough is at least $1.44 Million dollars as of 16 August 2007. Steven Keough owns over 17,600 units of Surmodics stock worth over $857,882 and over the last 21 years Steven sold SRDX stock worth over $578,050.
Steven has made over 2 trades of the Surmodics stock since 2006, according to the Form 4 filled with the SEC. Most recently Steven exercised 17,600 units of SRDX stock worth $460,768 on 16 August 2007.
The largest trade Steven's ever made was exercising 17,600 units of Surmodics stock on 16 August 2007 worth over $460,768. On average, Steven trades about 3,154 units every 24 days since 2004. As of 16 August 2007 Steven still owns at least 21,868 units of Surmodics stock.
You can see the complete history of Steven Keough stock trades at the bottom of the page.
Steven's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.
Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj und Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Surmodics executives and other stock owners filed with the SEC include: